Investor Relations

Biodel Inc. is a specialty pharmaceutical company that develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. Biodel's products are created by utilizing the company's proprietary VIAdelâ„¢ technology, which enables rapid delivery of drugs into the blood through various routes of administration. Faster onset of action and non-invasive routes of delivery improve the efficacy, safety, compliance and convenience for patients.
NASD: BIOD
Jul 3, 2008
1:14 PM ET
$11.73   + 0.01


Recent Press Releases
Jun 11, 2008 Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors
Jun 4, 2008 Biodel Inc. to Present at the Canaccord Adams Diabetes and Obesity Conference on June 6th 2008
View All Press Releases »